Results 41 to 50 of about 17,663 (255)

Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios

International Journal of Cardiology: Heart & Vasculature, 2018
Atrial fibrillation (AF) has become the most prevalent arrhythmia and it will increase the risk of ischemic stroke, heart failure, mortality, sudden cardiac death, myocardial infarction, and dementia.
Ting-Yung Chang, Jo-Nan Liao, Tze-Fan Chao, Jennifer Jeanne Vicera, Chin-Yu Lin, Ta-Chuan Tuan, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Fa-Po Chung, Shih-Ann Chen   +11 more
doaj   +1 more source

Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management [PDF]

, 2017
Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation ...
Cheung, KS, Leung, WK
core   +1 more source

Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants. [PDF]

, 2018
Randomised controlled trials (RCTs) provide the reference standard for comparing the efficacy of one therapy or intervention with another. However, RCTs have restrictive inclusion and exclusion criteria; thus, they are not fully representative of an ...
Camm, AJ, Fox, KAA
core   +1 more source

Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting [PDF]

BioMed Research International, 2014
The field of oral anticoagulation has evolved with the arrival of non-vitamin K antagonist oral anticoagulants (NOACs) including an anti-IIa agent (dabigatran etexilate) and anti-Xa agents (rivaroxaban and apixaban). The main specificities of these drugs are predictable pharmacokinetics and pharmacodynamics but special attention should be paid in the ...
Anne-Sophie Dincq, Sarah Lessire, Jonathan Douxfils, Jean-Michel Dogné, Maximilien Gourdin, François Mullier   +5 more
openaire   +3 more sources

How to effectively reverse life-thretening effects of non-vitamin K oral anticoagulants?

Journal of Education, Health and Sport, 2017
For several decades the vitamin K antagonist oral anticoagulants were the only outpatient therapy that existed to reduce the risk of stroke and thromboembolism until non-vitamin K oral anticoagulants (NOACs).
Łukasz Wołowiec, Joanna Banach, Daniel Rogowicz, Magdalena Węglarz, Walery Zukow, Władysław Sinkiewicz   +5 more
doaj   +3 more sources

Comparison of ََQuality of Life and Treatment Satisfaction among Sample of Iraqi Patients Using Anticoagulant Therapy (Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants)

مجلة كلية الطب
Background: Oral anticoagulation medication, warfarin and non-vitamin k antagonist oral anticoagulants  (NOAC) may require long term use which may affect patients’ satisfaction with their treatment and their quality of life (QOL).  Objective: To compare
Basma Z. Al-Metwali, Tuqa M. AL-Ameen
doaj   +1 more source

Similar outcomes between vitamin K and non-vitamin K antagonist oral anticoagulants associated intracerebral hemorrhage

Journal of the Formosan Medical Association, 2020
Background: The application of non-vitamin K antagonist oral anticoagulant (NOAC) reduces the risk of intracerebral hemorrhage (ICH) in comparison with vitamin K antagonist (VKA).
Szu-Ju Chen, Shin-Joe Yeh, Sung-Chun Tang, Shin-Yi Lin, Li-Kai Tsai, Jiann-Shing Jeng   +5 more
doaj   +1 more source

Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. [PDF]

, 2015
Perioperative management of patients treated with the non-vitamin K antagonist oral anticoagulants is an ongoing challenge. Due to the lack of good clinical studies involving adequate monitoring and reversal therapies, management requires knowledge and ...
Albaladejo, Pierre, Faraoni, David, Fontana, Pierre, Levy, Jerrold H, Samama, Charles-Marc   +4 more
core   +3 more sources

Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe [PDF]

Open Heart, 2019
Background In Fontan patients with atrial arrhythmias (AA), non-vitamin K antagonist oral anticoagulants(NOACs) have a class III recommendation according to the Pediatric & Congenital Electrophysiology Society (PACES)/Heart Rhythm Society (HRS) guideline in 2014, due to lack of data on outcomes as opposed to ...
Yang, Hayang, Veldtman, Gruschen R., Bouma, Berto J., Budts, Werner, Niwa, Koichiro, Meijboom, Folkert, Scognamiglio, Giancarlo, Egbe, Alexander Chima, Schwerzmann, Markus, Broberg, Craig, Morissens, Marielle, Buber, Jonathan, Tsai, Shane, Polyzois, Ioannis, Post, Martijn C., Greutmann, Matthias, Van Dijk, Arie, Mulder, Barbara J.M., Aboulhosn, Jamil   +18 more
openaire   +11 more sources

Prevention of thromboembolic complications in patients with atrial fibrillation and obesity

Annales Academiae Medicae Silesiensis, 2023
Atrial fibrillation (AF) is an arrhythmia that occurs in 1–2% of the population. Chronic oral anticoagulation is recommended in the group of patients with AF to prevent thromboembolic complications. Obesity is a factor contributing to the development and
Izabela Kolasa, Beata Średniawa
doaj   +1 more source